Weight Loss Surgeries Decline as GLP-1 Use Surges: Implications for Patients

Recent research indicates a notable decline in the number of individuals opting for bariatric surgery, a procedure traditionally regarded as a leading solution for significant weight loss. This shift is largely attributed to the rising popularity of GLP-1 medications and various weight management programs, which have become increasingly accessible.

A study conducted by researchers at Loyola University Chicago analyzed trends in bariatric surgeries from 2020 to 2024, revealing a decrease in the overall number of procedures performed across the United States. The findings were presented at the American Society for Metabolic and Bariatric Surgery (ASMBS) Annual Meeting, although they have yet to be published in a peer-reviewed journal. This research reflects changing patient preferences and the evolving landscape of obesity treatments.

Bariatric surgery encompasses various procedures, including sleeve gastrectomy and gastric bypass, both of which have been proven effective for individuals with severe obesity. However, the study highlights that as non-invasive treatments gain traction, fewer patients are choosing surgical options. Data from the ACS-MBSAQIP, a national database tracking bariatric surgeries, showed that after peaking in 2022, the number of surgeries has since declined.

Among the notable trends, the frequency of sleeve gastrectomy—a procedure that reduces stomach size—has decreased, although it remains the most frequently performed surgery. Conversely, Roux-en-Y gastric bypass surgeries have seen an uptick, especially as many patients who initially underwent sleeve gastrectomy later opt for this more complex procedure to enhance weight loss or address complications.

As the landscape of weight loss treatments shifts, medical experts emphasize the importance of individual choices. Dr. John DeBarros, Chief Medical Officer at Pivot Weight Loss Center, notes that the decision between surgical and non-surgical options should be based on thorough research and discussions with qualified healthcare providers. He expresses concern when patients might forgo surgery simply because they perceive GLP-1 medications as a less intimidating option, especially for those with severe obesity.

Dr. Sergey Terushkin, a bariatric surgeon at ThinEra, echoes similar sentiments, acknowledging the significant role GLP-1 drugs have played in weight management. He observes that many patients who struggled with traditional methods are now finding success with these medications. However, both experts stress that bariatric surgery remains the most effective long-term treatment, capable of addressing various health conditions linked to obesity.

Patients considering their options for weight loss should engage in open conversations with healthcare professionals. Understanding the severity of obesity, medical history, and the potential for long-term medication adherence is crucial in determining the most suitable approach. While bariatric surgery has a wealth of data supporting its effectiveness, the right choice ultimately varies from person to person, highlighting the need for personalized treatment plans. As the field continues to evolve, staying informed about available options will help individuals make the best decisions for their health and well-being.